Quality is real on both the print and the outlook, but the price already reflects it. You're paying for what you can see.
Overall read
7.1/10
Priced for it
The three reads · this quarter
Quality is real on both the print and the outlook, but the price already reflects it. You're paying for what you can see.
Overall read
7.1/10
Priced for it
The three reads · this quarter
The standing reads · change less often
Moat
Slim edge
US regulated market moat from CGT, controlled substances and govt contracts, but limited scale and emerging market drag.
Key variables
No key-variables snapshot yet.
Walk the talk
Not enough tracked guidance to grade yet.
FY27 guidance: 30-40% revenue growth, 50-60% PAT growth.
Latest · newest first
3d ago · M&A / Investment
Proposed incorporation of subsidiary in Canada for business expansion.
3d ago · M&A / Investment
Proposed incorporation of wholly owned subsidiary in Mexico for business expansion.
5d ago · M&A / Investment
Senores Pharmaceuticals provides corporate guarantee for subsidiary's credit facilities from ICICI Bank.
4w ago · Business Update
Company releases media update for Q1FY27.
4w ago · Business Update
Appointed Ms Anjali Shah as Assistant Vice President - Finance (SMP) effective July 27, 2026.
Where it sits